News | May 15, 2022
Merck KGaA first quarter earnings grows on higher volumes, margins
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
In this role, Romanelli will have P&L responsibility for Merck’s US $22 billion international human health business and lead a team of 14,000 colleagues in more than 75 markets outside of the U.S
Supply increase to help meet growing global demand
No new studies have been requested
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Company expects strong organic growth in sales, EBITDA in 2022
Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16
Subscribe To Our Newsletter & Stay Updated
